Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Swiss National Bank

Swiss National Bank boosted its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 0.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 166,200 shares of the biopharmaceutical company’s stock after buying an additional 800 shares during the quarter. Swiss National Bank’s holdings in Fate Therapeutics were worth $9,851,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. US Bancorp DE lifted its position in shares of Fate Therapeutics by 51.3% during the 2nd quarter. US Bancorp DE now owns 790 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 268 shares during the period. Corepath Wealth Partners LLC acquired a new position in Fate Therapeutics during the second quarter worth $215,000. Profund Advisors LLC purchased a new stake in Fate Therapeutics during the second quarter worth $204,000. JustInvest LLC purchased a new stake in Fate Therapeutics during the second quarter worth $215,000. Finally, Bridgefront Capital LLC grew its holdings in Fate Therapeutics by 5.8% in the second quarter. Bridgefront Capital LLC now owns 2,769 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 153 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

NASDAQ:FATE opened at $43.28 on Friday. The company has a market cap of $4.13 billion, a P/E ratio of -20.42 and a beta of 1.46. The firm’s 50 day moving average is $54.40 and its two-hundred day moving average is $66.87. Fate Therapeutics, Inc. has a fifty-two week low of $40.33 and a fifty-two week high of $119.85.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.13. The firm had revenue of $14.23 million for the quarter, compared to analysts’ expectations of $8.67 million. Fate Therapeutics had a negative return on equity of 28.25% and a negative net margin of 359.66%. The firm’s revenue for the quarter was up 88.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.36) earnings per share. As a group, research analysts anticipate that Fate Therapeutics, Inc. will post -2.27 earnings per share for the current year.

A number of equities research analysts recently commented on FATE shares. SVB Leerink lowered their price objective on shares of Fate Therapeutics from $118.00 to $115.00 and set an “outperform” rating on the stock in a research note on Monday, November 8th. Guggenheim lowered their price target on shares of Fate Therapeutics from $107.00 to $78.00 in a research report on Monday, January 3rd. Roth Capital cut their price objective on Fate Therapeutics from $90.00 to $60.00 and set a “neutral” rating for the company in a research report on Friday, November 5th. Cowen assumed coverage on Fate Therapeutics in a report on Tuesday, December 7th. They set an “outperform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $122.00 price target on shares of Fate Therapeutics in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $106.47.

In related news, CFO Edward J. Dulac III sold 1,770 shares of the firm’s stock in a transaction dated Tuesday, January 11th. The stock was sold at an average price of $48.45, for a total transaction of $85,756.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Bahram Valamehr sold 5,596 shares of the stock in a transaction that occurred on Monday, January 10th. The shares were sold at an average price of $46.38, for a total transaction of $259,542.48. The disclosure for this sale can be found here. Insiders sold 151,702 shares of company stock worth $7,925,537 in the last 90 days. 18.58% of the stock is currently owned by insiders.

About Fate Therapeutics

Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.

Featured Story: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.